Kendra S. Carmon

Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models

This study shows that combining LGR5 and MET-targeting antibody-drug conjugates with different payloads improves efficacy and delays tumor relapse in colorectal cancer models.

Bispecific antibody-drug conjugates targeting EGFR and LGR5 exert potent antitumor activity in colorectal cancer models

EGFR:LGR5 bispecific antibody-drug conjugates show strong antitumor effects and outperform other ADCs in colorectal cancer models.

Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing Ferroptosis

This study shows that TP53-deficient tumors resist DS-7300a therapy, but inducing ferroptosis can enhance its efficacy in these cancers.

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models

This study shows cetuximab increases LGR5 expression and improves the efficacy of LGR5-targeting ADCs in colorectal cancer models.

Anti-tumor activity of camptothecin analog conjugate of a RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancer.

This study develops and tests a camptothecin analog conjugate targeting LGR4/5/6 in CRC models, showing potent anti-tumor activity with minimal toxicity.

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer

This study develops and tests EREG-targeting ADCs showing efficacy in both RAS mutant and wildtype CRC, with high potency and safety in preclinical models.

Anti-GPR56 monoclonal antibody potentiates GPR56-mediated Src-Fak signaling to modulate cell adhesion

This study identifies an anti-GPR56 monoclonal antibody that enhances Src-Fak signaling and cell adhesion through a novel extracellular domain-dependent mechanism.